EP4011219A1 - Liquid composition for inhalation for electronic cigarettes with reduced cytotoxicity - Google Patents
Liquid composition for inhalation for electronic cigarettes with reduced cytotoxicity Download PDFInfo
- Publication number
- EP4011219A1 EP4011219A1 EP21210563.9A EP21210563A EP4011219A1 EP 4011219 A1 EP4011219 A1 EP 4011219A1 EP 21210563 A EP21210563 A EP 21210563A EP 4011219 A1 EP4011219 A1 EP 4011219A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- percentage
- volume
- equal
- composition
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
- A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
- A24B15/42—Treatment of tobacco products or tobacco substitutes by chemical substances by organic and inorganic substances
Definitions
- the present invention relates to a liquid inhalation composition for electronic cigarettes with reduced cytotoxicity.
- the heated-tobacco inhalation systems are those which are most similar to traditional smoking for smokers, both in terms of the flavoring of the tobacco and of consumption methods and times, similar to those of a cigarette.
- some toxic substances contained in tobacco are formed even before the combustion thereof, such as, in addition to nicotine, nitrosamines. These substances are therefore not eliminated by reducing the combustion temperature to no more than 350°C.
- compositions for electronic cigarettes do not contain such toxic or carcinogenic substances, apart from a controlled amount of nicotine, which is essential to make the inhalation of the composition pleasant by the traditional smoker. Furthermore, the possibility of flavoring the composition in various manners forms a further attraction.
- the base composition which consists for the most part of a mixture of propylene glycol and glycerol in a volume ratio of 50:50, or for a denser vapor of 30:70, has an inherent toxicity, albeit much more reduced than that of a traditional cigarette and the heated-tobacco system described above.
- the present invention relates to a composition for inhalation by means of an electronic cigarette comprising:
- the invention also relates to a base composition
- a base composition comprising:
- the invention still further relates to a kit comprising:
- the present invention is directed to a composition for inhalation by means of electronic cigarettes comprising:
- the glycerol/propylene glycol mixture is at a volume ratio between 50:50 and 70:30.
- the percentage by volume of the glycerol/propylene glycol mixture will not be greater than 90%.
- the glycerol is preferably vegetable glycerol.
- the percentage of nicotine optionally present in the composition should not be greater than the amount allowed by current legislation, in particular it should be less than or equal to 20 mg/ml.
- the water is preferably demineralized water.
- the flavorings can be of any type normally used for electronic cigarettes, such as fruit flavorings, tobacco flavorings, mentholates or mixtures thereof.
- the flavorings can be added to a base composition which does not contain them directly by the smoker. In this case, glycol-based flavorings are available to add to the composition as desired.
- the invention further relates to a base composition
- a base composition comprising
- the pH adjuster is preferably an organic or inorganic acid, more preferably selected from orthophosphoric acid, lactic acid and citric acid.
- the weight percentage of the pH adjuster in the composition depends on both the nature of the pH adjuster and the percentage of the various components used in the composition. For example, in a composition containing about 90% by volume of 50:50 glycerol/propylene glycol mixture, about 5% water, about 10% flavorings (apple/kiwi), nicotine 8 mg/ml, orthophosphoric acid in a weight percentage of 0.1% adjusted the pH of the composition to 7.5.
- the pH is preferably between 7.2 and 7.6, more preferably between 7.3 and 7.6 or between 7.4 and 7.6 or is of about 7.5.
- the invention still further relates to a kit comprising:
- the present invention originates from the evidence that the known compositions for electronic cigarettes have a basic pH.
- the present Applicant has conducted experiments and has verified that such a basic pH is responsible for a certain cytotoxicity towards lung cells (human lung fibroblasts).
- the Applicant has also discovered that by lowering the pH of the composition to a pH between 7 and 7.6, such toxicity is substantially reduced if not eliminated.
- cytotoxicity of a composition according to the invention towards compositions of the prior art was evaluated through the MTT test: cell survival test with human fibroblasts of pulmonary origin grown in monolayer for the evaluation of the biocompatibility of smoke with mucous membranes.
- the test aims at evaluating the cytotoxicity of the smoke condensate obtained with electronic cigarettes with pH correction to neutrality according to the invention on a cell culture of human lung fibroblasts, as described in the UNI EN ISO 10993-5 and ISO 4387:2019 standards related to the biological evaluation of medical devices, appropriately modified for the purpose.
- the cytotoxicity of the condensate obtained by simulating the exposure to which the user of the electronic cigarette is subjected is an indicator of the safe use of the device in hand and the overall toxicity thereof towards the respiratory epithelium.
- the method used is that of MTT, which is simple and reproducible, originally developed by Mossman.
- An increase or decrease in viable cells results in a concomitant change in absorbance which can be regarded as an indicator of the degree of cytotoxicity caused by exposure to the test substances.
- the cells are also examined under a microscope after contact with the sample to evaluate any changes in the morphology thereof, membrane integrity or any lysis phenomena.
- HPF Human Lung Fibroblasts
- Cigarette smoke is sampled using a smoke machine consisting of a vacuum system and a 100 ml flask connected to an electronic cigarette.
- the electronic cigarette is positioned vertically on an inert plastic fitting. The positioning allows the metal resistance inside the tank and used to heat the liquid to always remain in contact with the liquid itself, as indicated by the manufacturer.
- the electronic cigarette loaded with the appropriate liquid was left to rest about 20 minutes before aspiration, so that the cotton inside the tank was correctly moistened with liquid, after which the first 2/3 puffs were discarded.
- the flask is connected by silicone tubes to a flow meter inside the instrument, which is in turn connected to a vacuum pump and to a PC with control software.
- the presence of a flow meter allows the constant setting of the aspiration flow.
- 30 ml of sterile medium were used for the preparation of the condensates.
- An aspiration/inhalation simulation is performed with a duration of 3" with a pause lasting 45" between one aspiration and the other, to facilitate the collection of the condensate in the medium, keeping the flask constantly under stirring during the experiment, in accordance with ISO 4387:2019.
- the aspiration flow is regulated at 1 L/min. 150 aspiration/inhalation cycles are performed, equal to 25 traditional cigarettes.
- the smoke from the electronic cigarette, loaded with the special liquid at the beginning of the session, is continuously sampled for the expected number of cycles.
- the medium with the condensate obtained from such an experiment was brought to pH 7.5 with lactic acid and subjected to cytotoxicity tests.
- Human lung cells were seeded in 96-well plates and allowed to grow for 24h at 37°C and 5% CO 2 . On the second day, the medium was removed and replaced by the freshly prepared condensate from the cigarette to be tested.
- the tested concentrations are the condensate as is and the subsequent serial 1:2 dilutions thereof in medium.
- the cytotoxicity test (MTT) was then performed to evaluate the cell survival percentage.
- the culture medium is aspirated and the cells incubated in 100 ⁇ l/well of a 1 mg/ml solution of MTT, for 2 hours at 37°C.
- the solution is removed and replaced by 200 ⁇ l/well of DMSO with subsequent 30' of incubation at room temperature and stirring at medium speed.
- the absorbance at 570 nm is read with a colorimeter (Tecan INFINITE F200) provided with a plate reader by subtracting the background reading at 650 nm.
- % of cell viability OD 570 nm ⁇ 650 nm product tested / OD 570 nm ⁇ 650 nm white ⁇ 100 .
- IC 50 Inhibiting Concentration 50
- Conc > 50 first concentration which gave a cell viability above 50%
- Conc ⁇ 50 first concentration which gave a cell viability less than 50%
- a reduction in cell viability > 30% is considered a cytotoxic effect.
- Figure 1 shows the graph of cell viability vs concentration for the positive control (SLS).
- Figure 2 shows the graph of cell viability vs concentration for the composition of the invention at pH 7.5.
- Figure 3 shows the graph of cell viability vs concentration for the electronic cigarette composition of the prior art (pH 8.9).
- Figure 4 shows the graph of cell viability vs concentration for the HEETS Turquoise selection heated-tobacco cigarette.
- composition for electronic cigarettes according to the invention is much less cytotoxic than both the composition of the prior art without acidity adjuster and, to an even greater extent, the heated-tobacco cigarette.
- the invention further relates to a pH adjuster acid for use in preventing pulmonary cytotoxicity in subjects intaking vapors by means of electronic cigarettes, in which said pH adjuster acid is added to an electronic cigarette composition comprising a glycerol/propylene glycol mixture in a percentage by volume between 80% and 99%, optionally water in a percentage by volume less than or equal to 6%, preferably less than or equal to 5%, optionally nicotine in a percentage by weight/volume not exceeding 0.2%, optionally flavorings in a percentage by volume less than or equal to 15%, preferably less than or equal to 10%, and in which said pH adjuster acid gives said composition a pH between 7.0 and 7.6.
- Said pH adjuster acid is preferably selected from orthophosphoric acid, lactic acid and citric acid and the composition for electronic cigarettes is preferably as defined above.
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- The present invention relates to a liquid inhalation composition for electronic cigarettes with reduced cytotoxicity.
- Recognizing that cigarette smoking causes serious damage to health has long prompted the industry to develop alternative forms of inhalation which can give smokers adequate satisfaction and effectively replace traditional cigarettes in daily use.
- Starting from the evidence that the intake of nicotine is a key factor which causes the continuous desire to smoke in smokers, but that the greatest damage comes from the substances of the high-temperature combustion of tobacco, such as polycyclic aromatic hydrocarbons, tar and carbon monoxide, the art has followed two parallel paths. On the one hand, systems have been developed which include heating tobacco at a controlled temperature (generally no higher than 350°C), so as to avoid the harmful effects of high-temperature combustion. On the other hand, so-called "electronic cigarettes" have been created which vaporize a liquid comprising, in addition to a base capable of providing a sufficiently dense body to the vapor released, also a controlled amount of nicotine and various types of flavorings.
- The heated-tobacco inhalation systems are those which are most similar to traditional smoking for smokers, both in terms of the flavoring of the tobacco and of consumption methods and times, similar to those of a cigarette. However, it should be remembered that some toxic substances contained in tobacco are formed even before the combustion thereof, such as, in addition to nicotine, nitrosamines. These substances are therefore not eliminated by reducing the combustion temperature to no more than 350°C.
- The compositions for electronic cigarettes, on the other hand, do not contain such toxic or carcinogenic substances, apart from a controlled amount of nicotine, which is essential to make the inhalation of the composition pleasant by the traditional smoker. Furthermore, the possibility of flavoring the composition in various manners forms a further attraction.
- Therefore, electronic cigarettes largely solve the toxicity problems associated with tobacco use, even if they are not completely safe. In fact, the base composition, which consists for the most part of a mixture of propylene glycol and glycerol in a volume ratio of 50:50, or for a denser vapor of 30:70, has an inherent toxicity, albeit much more reduced than that of a traditional cigarette and the heated-tobacco system described above.
- Therefore, the problem of being able to further lower the toxicity of a composition for inhalation by means of electronic cigarettes so as to make the prolonged consumption thereof much safer is still felt.
- The aforesaid technical problem is substantially solved by a composition comprising the technical features set out in one or more of the appended claims, the definitions of which form an integral part of the present description for the purpose of sufficiency of description.
- Therefore, the present invention relates to a composition for inhalation by means of an electronic cigarette comprising:
- a glycerol/propylene glycol mixture in a percentage by volume between 80% and 99%;
- optionally, water in a percentage by volume less than or equal to 6%, preferably less than or equal to 5%;
- optionally, nicotine in a percentage by weight/volume not exceeding 0.2%;
- optionally, flavorings in a percentage by volume less than or equal to 15%, preferably less than or equal to 10%;
- a pH adjuster,
in which the composition has a pH between 7.0 and 7.6. - The invention also relates to a base composition comprising:
- a glycerol/propylene glycol mixture in a percentage by volume between 93% and 99%;
- optionally, water in a percentage by volume less than or equal to 6%, preferably less than or equal to 5%;
- optionally, nicotine in a percentage by weight/volume not exceeding 0.2%;
- a pH adjuster, in which the base composition has a pH between 7.0 and 7.6.
- The invention still further relates to a kit comprising:
- a) a container comprising a base composition comprising
- a glycerol/propylene glycol mixture in a percentage by volume between 93% and 99%;
- optionally, water in a percentage by volume less than or equal to 6%, preferably less than or equal to 5%;
- optionally, nicotine in a percentage by weight/volume not exceeding 0.2%;
- a pH adjuster, in which the base composition has a pH between 7.0 and 7.6;
- b) one or more containers comprising flavorings in a percentage by volume less than or equal to 10%.
- Further features and advantages of the present invention will become more apparent from the indicative and thus non-limiting description of a preferred, but not exclusive embodiment of the invention.
-
-
Figure 1 depicts a graph of cell viability vs composition concentration with a control compound; -
Figure 2 depicts a graph of cell viability vs composition concentration with a composition according to the invention; -
Figure 3 depicts a graph of cell viability vs composition concentration with a composition for electronic cigarettes according to the prior art; -
Figure 4 depicts a graph of cell viability vs composition concentration with a heated-tobacco system according to the prior art. - The present invention is directed to a composition for inhalation by means of electronic cigarettes comprising:
- a glycerol/propylene glycol mixture in a percentage by volume between 80% and 99%;
- optionally, water in a percentage by volume less than or equal to 6%, preferably less than or equal to 5%;
- optionally, nicotine in a percentage by weight/volume not exceeding 0.2%;
- optionally, flavorings in a percentage by volume less than or equal to 15%, preferably less than or equal to 10%;
- a pH adjuster,
in which the composition has a pH between 7.0 and 7.6. - The glycerol/propylene glycol mixture is at a volume ratio between 50:50 and 70:30.
- If the composition contains flavorings, the percentage by volume of the glycerol/propylene glycol mixture will not be greater than 90%.
- The glycerol is preferably vegetable glycerol.
- The percentage of nicotine optionally present in the composition should not be greater than the amount allowed by current legislation, in particular it should be less than or equal to 20 mg/ml.
- The water is preferably demineralized water.
- The flavorings can be of any type normally used for electronic cigarettes, such as fruit flavorings, tobacco flavorings, mentholates or mixtures thereof. The flavorings can be added to a base composition which does not contain them directly by the smoker. In this case, glycol-based flavorings are available to add to the composition as desired.
- Therefore, the invention further relates to a base composition comprising
- a glycerol/propylene glycol mixture in a percentage by volume between 93% and 99%;
- optionally, water in a percentage by volume less than or equal to 6%, preferably less than or equal to 5%;
- optionally, nicotine in a percentage by weight/volume not exceeding 0.2%;
- a pH adjuster, in which the base composition has a pH between 7.0 and 7.6.
- The pH adjuster is preferably an organic or inorganic acid, more preferably selected from orthophosphoric acid, lactic acid and citric acid.
- The weight percentage of the pH adjuster in the composition depends on both the nature of the pH adjuster and the percentage of the various components used in the composition. For example, in a composition containing about 90% by volume of 50:50 glycerol/propylene glycol mixture, about 5% water, about 10% flavorings (apple/kiwi),
nicotine 8 mg/ml, orthophosphoric acid in a weight percentage of 0.1% adjusted the pH of the composition to 7.5. - The pH is preferably between 7.2 and 7.6, more preferably between 7.3 and 7.6 or between 7.4 and 7.6 or is of about 7.5.
- The invention still further relates to a kit comprising:
- a) a container comprising a base composition comprising
- a glycerol/propylene glycol mixture in a percentage by volume between 93% and 99%;
- optionally, water in a percentage by volume less than or equal to 6%, preferably less than or equal to 5%;
- optionally, nicotine in a percentage by weight/volume not exceeding 0.2%;
- a pH adjuster, in which the base composition has a pH between 7.0 and 7.6;
- b) one or more containers comprising flavorings in a percentage by volume less than or equal to 10%.
- The present invention originates from the evidence that the known compositions for electronic cigarettes have a basic pH. The present Applicant has conducted experiments and has verified that such a basic pH is responsible for a certain cytotoxicity towards lung cells (human lung fibroblasts). The Applicant has also discovered that by lowering the pH of the composition to a pH between 7 and 7.6, such toxicity is substantially reduced if not eliminated.
- The cytotoxicity of a composition according to the invention towards compositions of the prior art was evaluated through the MTT test: cell survival test with human fibroblasts of pulmonary origin grown in monolayer for the evaluation of the biocompatibility of smoke with mucous membranes.
- The test aims at evaluating the cytotoxicity of the smoke condensate obtained with electronic cigarettes with pH correction to neutrality according to the invention on a cell culture of human lung fibroblasts, as described in the UNI EN ISO 10993-5 and ISO 4387:2019 standards related to the biological evaluation of medical devices, appropriately modified for the purpose.
- The cytotoxicity of the condensate obtained by simulating the exposure to which the user of the electronic cigarette is subjected is an indicator of the safe use of the device in hand and the overall toxicity thereof towards the respiratory epithelium.
- The method used is that of MTT, which is simple and reproducible, originally developed by Mossman.
- An increase or decrease in viable cells results in a concomitant change in absorbance which can be regarded as an indicator of the degree of cytotoxicity caused by exposure to the test substances. The cells are also examined under a microscope after contact with the sample to evaluate any changes in the morphology thereof, membrane integrity or any lysis phenomena.
- A line of Human Lung Fibroblasts (HPF) was used. Source: Innoprot. The cells are cultured in MEM containing 10% FBS and antibiotics.
- Cigarette smoke is sampled using a smoke machine consisting of a vacuum system and a 100 ml flask connected to an electronic cigarette. The electronic cigarette is positioned vertically on an inert plastic fitting. The positioning allows the metal resistance inside the tank and used to heat the liquid to always remain in contact with the liquid itself, as indicated by the manufacturer.
- The electronic cigarette loaded with the appropriate liquid was left to rest about 20 minutes before aspiration, so that the cotton inside the tank was correctly moistened with liquid, after which the first 2/3 puffs were discarded.
- The flask is connected by silicone tubes to a flow meter inside the instrument, which is in turn connected to a vacuum pump and to a PC with control software. The presence of a flow meter allows the constant setting of the aspiration flow. 30 ml of sterile medium were used for the preparation of the condensates. An aspiration/inhalation simulation is performed with a duration of 3" with a pause lasting 45" between one aspiration and the other, to facilitate the collection of the condensate in the medium, keeping the flask constantly under stirring during the experiment, in accordance with ISO 4387:2019.
- The aspiration flow is regulated at 1 L/min. 150 aspiration/inhalation cycles are performed, equal to 25 traditional cigarettes. The smoke from the electronic cigarette, loaded with the special liquid at the beginning of the session, is continuously sampled for the expected number of cycles. The medium with the condensate obtained from such an experiment was brought to pH 7.5 with lactic acid and subjected to cytotoxicity tests.
- Human lung cells were seeded in 96-well plates and allowed to grow for 24h at 37°C and 5% CO2. On the second day, the medium was removed and replaced by the freshly prepared condensate from the cigarette to be tested.
- In order to determine the IC50 value (Inhibiting Concentration 50) at the end of the experiment, the tested concentrations are the condensate as is and the subsequent serial 1:2 dilutions thereof in medium.
- Each sample was tested in sixfold. Untreated cells were used as blank and as positive control the cells were treated with a surfactant of known toxicity (Sodium Lauryl Sulfate - SLS) dissolved in the culture medium at concentrations between 0.5 mg/ml and 0.03 mg/ml.
- After 24 hours of incubation with the sample and the control, the cytotoxicity test (MTT) was then performed to evaluate the cell survival percentage.
- The culture medium is aspirated and the cells incubated in 100 µl/well of a 1 mg/ml solution of MTT, for 2 hours at 37°C. The solution is removed and replaced by 200 µl/well of DMSO with subsequent 30' of incubation at room temperature and stirring at medium speed.
- The absorbance at 570 nm is read with a colorimeter (Tecan INFINITE F200) provided with a plate reader by subtracting the background reading at 650 nm.
-
-
- %>50 = first cell viability obtained above 50%
- %<50 = first cell viability obtained less than 50%.
- The following acceptability criteria of the method were adopted:
- for the blank: the mean OD value of the replicates should be ≥ 0.2, the standard deviation should be ≤ 18%, the mean of two columns of blanks should not differ by more than 15%;
- for the positive control (CP): the IC50 of the SLS positive control should be 0.10 mg/ml ± 0.03, the standard deviation should be ≤ 18%;
- for the sample: standard deviation should be ≤ 18%.
- A reduction in cell viability > 30% is considered a cytotoxic effect.
- The samples used were:
- composition for electronic cigarettes according to the invention, comprising 90% by volume of 50:50 glycerol/propylene glycol mixture, water about 5%, flavorings (apple/kiwi) about 10%,
nicotine 8 mg/ml, pH adjuster: acid lactic up to pH 7.5; - composition for electronic cigarettes of the prior art, comprising 90% by volume of 50:50 glycerol/propylene glycol mixture, water about 5%, flavorings (apple/kiwi) about 10%,
nicotine 8 mg/ml, pH 8.9; - HEETS Turquoise selection cigarette 3172 /20-06 (heated-tobacco cigarette), pH 7.9.
-
Figure 1 shows the graph of cell viability vs concentration for the positive control (SLS). -
Figure 2 shows the graph of cell viability vs concentration for the composition of the invention at pH 7.5. -
Figure 3 shows the graph of cell viability vs concentration for the electronic cigarette composition of the prior art (pH 8.9). -
Figure 4 shows the graph of cell viability vs concentration for the HEETS Turquoise selection heated-tobacco cigarette. - The following IC50 values were calculated from the data of such experiments:
- positive control IC50 = 0.09 ml/ml
- composition for electronic cigarettes according to the invention IC50»1 ml/ml (non-cytotoxic at the highest concentration tested)
- composition for electronic cigarettes of the prior art IC50 = 0.93 ml/ml
- IC50 heated-tobacco cigarette = 0.19 ml/ml.
- From the above it is apparent that the composition for electronic cigarettes according to the invention is much less cytotoxic than both the composition of the prior art without acidity adjuster and, to an even greater extent, the heated-tobacco cigarette.
- Therefore, the invention further relates to a pH adjuster acid for use in preventing pulmonary cytotoxicity in subjects intaking vapors by means of electronic cigarettes, in which said pH adjuster acid is added to an electronic cigarette composition comprising a glycerol/propylene glycol mixture in a percentage by volume between 80% and 99%, optionally water in a percentage by volume less than or equal to 6%, preferably less than or equal to 5%, optionally nicotine in a percentage by weight/volume not exceeding 0.2%, optionally flavorings in a percentage by volume less than or equal to 15%, preferably less than or equal to 10%, and in which said pH adjuster acid gives said composition a pH between 7.0 and 7.6.
- Said pH adjuster acid is preferably selected from orthophosphoric acid, lactic acid and citric acid and the composition for electronic cigarettes is preferably as defined above.
- It is apparent that only some particular embodiments of the present invention have been described, to which those skilled in the art will be able to make all changes required to adapt it to particular applications, without departing from the scope of protection of the present invention.
Claims (12)
- A composition for inhalation by means of an electronic cigarette comprising:- a glycerol/propylene glycol mixture in a percentage by volume between 80% and 99%;- optionally, water in a percentage by volume less than or equal to 6%, preferably less than or equal to 5%;- optionally, nicotine in a percentage by weight/volume not exceeding 0.2%;- optionally, flavorings in a percentage by volume less than or equal to 15%, preferably less than or equal to 10%;- a pH adjuster,
wherein the composition has a pH between 7.0 and 7.6. - The composition according to claim 1, wherein the glycerol/propylene glycol mixture is at a volume ratio between 50:50 and 70:30.
- The composition according to claim 1 or 2, wherein, when the composition contains flavorings, the percentage by volume of the glycerol/propylene glycol mixture is no greater than 90%.
- The composition according to any one of claims 1 to 3, wherein the flavorings are selected from fruit, tobacco, mentholated flavorings or mixtures thereof.
- The composition according to any one of claims 1 to 4, wherein the pH adjuster is an organic or inorganic acid.
- The composition according to claim 5, wherein the pH adjuster is selected from orthophosphoric acid, lactic acid and citric acid.
- The composition according to any one of claims 1 to 6, wherein the pH is between 7.2 and 7.6, or between 7.3 and 7.6, or between 7.4 and 7.6, or is of about 7.5.
- The composition according to any one of claims 1 to 7, wherein the pH adjuster is orthophosphoric acid in a percentage by weight of about 0.1%.
- A base composition comprising:- a glycerol/propylene glycol mixture in a percentage by volume between 93% and 99%;- optionally, water in a percentage by volume less than or equal to 6%, preferably less than or equal to 5%;- optionally, nicotine in a percentage by weight/volume not exceeding 0.2%;- a pH adjuster, wherein the base composition has a pH between 7.0 and 7.6.
- A kit comprising:a) a container comprising a base composition comprising- a glycerol/propylene glycol mixture in a percentage by volume between 93% and 99%;- optionally, water in a percentage by volume less than or equal to 6%, preferably less than or equal to 5%;- optionally, nicotine in a percentage by weight/volume not exceeding 0.2%;- a pH adjuster, wherein the base composition has a pH between 7.0 and 7.6;b) one or more containers comprising flavorings in a percentage by volume less than or equal to 10%.
- A pH adjuster acid for use in preventing pulmonary cytotoxicity in subjects intaking vapors by means of electronic cigarettes, wherein said pH adjuster acid is added to an electronic cigarette composition comprising a glycerol/propylene glycol mixture in a percentage by volume between 80% and 99%, optionally water in a percentage by volume less than or equal to 6%, preferably less than or equal to 5%, optionally nicotine in a percentage by weight/volume not exceeding 0.2%, optionally flavorings in a percentage by volume less than or equal to 15%, preferably less than or equal to 10%, and wherein said pH adjuster acid gives said composition a pH between 7.0 and 7.6.
- The pH adjuster acid for use according to claim 11, wherein the composition is as defined in any one of claims 2 to 9.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102020000030173A IT202000030173A1 (en) | 2020-12-09 | 2020-12-09 | INHALATION LIQUID COMPOSITION FOR REDUCED CYTOTOXICITY ELECTRONIC CIGARETTES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP4011219A1 true EP4011219A1 (en) | 2022-06-15 |
| EP4011219B1 EP4011219B1 (en) | 2025-05-07 |
| EP4011219C0 EP4011219C0 (en) | 2025-05-07 |
Family
ID=74669409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP21210563.9A Active EP4011219B1 (en) | 2020-12-09 | 2021-11-25 | Liquid composition for inhalation for electronic cigarettes with reduced cytotoxicity |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP4011219B1 (en) |
| IT (1) | IT202000030173A1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130255702A1 (en) * | 2012-03-28 | 2013-10-03 | R.J. Reynolds Tobacco Company | Smoking article incorporating a conductive substrate |
| US20140096781A1 (en) * | 2012-10-08 | 2014-04-10 | R. J. Reynolds Tobacco Company | Electronic smoking article and associated method |
| WO2014190079A2 (en) * | 2013-05-22 | 2014-11-27 | Njoy, Inc. | Compositions, devices, and methods for nicotine aerosol delivery |
| CN110558605A (en) * | 2019-09-27 | 2019-12-13 | 深圳雾芯科技有限公司 | Electronic cigarette liquid |
| WO2020239907A1 (en) * | 2019-05-31 | 2020-12-03 | Jt International S.A. | Nicotine liquid formulation |
-
2020
- 2020-12-09 IT IT102020000030173A patent/IT202000030173A1/en unknown
-
2021
- 2021-11-25 EP EP21210563.9A patent/EP4011219B1/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130255702A1 (en) * | 2012-03-28 | 2013-10-03 | R.J. Reynolds Tobacco Company | Smoking article incorporating a conductive substrate |
| US20140096781A1 (en) * | 2012-10-08 | 2014-04-10 | R. J. Reynolds Tobacco Company | Electronic smoking article and associated method |
| WO2014190079A2 (en) * | 2013-05-22 | 2014-11-27 | Njoy, Inc. | Compositions, devices, and methods for nicotine aerosol delivery |
| WO2020239907A1 (en) * | 2019-05-31 | 2020-12-03 | Jt International S.A. | Nicotine liquid formulation |
| CN110558605A (en) * | 2019-09-27 | 2019-12-13 | 深圳雾芯科技有限公司 | Electronic cigarette liquid |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4011219B1 (en) | 2025-05-07 |
| IT202000030173A1 (en) | 2022-06-09 |
| EP4011219C0 (en) | 2025-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6030255B2 (en) | Method for preparing tobacco extract for electronic smoking device | |
| Tangerman et al. | Extra-oral halitosis: an overview | |
| FI83019C (en) | FOERFARANDE FOER TILLSAETTANDE AV AROMAEMNEN I TOBAK. | |
| RU2745735C1 (en) | Product | |
| Wheeler et al. | Does the burning of moxa (Artemisia vulgaris) in traditional Chinese medicine constitute a health hazard? | |
| Armitage et al. | The effect of inhalation volume and breath-hold duration on the retention of nicotine and solanesol in the human respiratory tract and on subsequent plasma nicotine concentrations during cigarette smoking | |
| JP2005503819A (en) | Activated carbon filter for reducing p-benzosemiquinone from tobacco mainstream smoke | |
| Bozhilova et al. | Optimization of aqueous aerosol extract (AqE) generation from e-cigarettes and tobacco heating products for in vitro cytotoxicity testing | |
| BR0309909B1 (en) | TSNA content reduction process in tobacco leaf | |
| Watson et al. | Determination of tar, nicotine, and carbon monoxide yields in the smoke of bidi cigarettes | |
| CN106556691B (en) | A method for detecting the effect of electronic cigarette products on the activity of cellular catalase | |
| EP4011219A1 (en) | Liquid composition for inhalation for electronic cigarettes with reduced cytotoxicity | |
| US10952460B2 (en) | Composition for a tobacco-free chew and method of manufacturing same | |
| Fukano et al. | Heme oxygenase-1 gene expression in human alveolar epithelial cells (A549) following exposure to whole cigarette smoke on a direct in vitro exposure system | |
| Lee et al. | Comparative genotoxicity testing of mainstream whole smoke from cigarettes which burn or heat tobacco | |
| CN106556692A (en) | It is a kind of for detecting method that electronics tobacco product secretes impact to cytoactive oxygen | |
| CN102423108B (en) | Tobacco composition of aromatic tobacco strips and fluecured tobacco strips and cigarette | |
| JPH0662824A (en) | Method for removing free radical from tobacco smoke | |
| Popa et al. | CO2 laser-photoacoustic study of exhaled breath produced by electronic vs. traditional cigarettes | |
| Moldoveanu et al. | Determination of benzene and toluene in exhaled cigarette smoke | |
| CN101238911B (en) | A method for post-processing cigarette products | |
| US12239957B2 (en) | Flow-through aerosol capture device | |
| Moldoveanu et al. | Determination of hydroxybenzenes in exhaled cigarette smoke | |
| CN107807233A (en) | Detect method of the electronics smoke sol water extract to cellular superoxide dismutase activity influence | |
| CN102221597A (en) | Organoleptic test method for consistency of cigarette style characteristic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20221012 |
|
| RBV | Designated contracting states (corrected) |
Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20240419 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602021030343 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A24B0015167000 Ipc: A24B0015420000 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20240705 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A24B 15/167 20200101ALI20240628BHEP Ipc: A24B 15/42 20060101AFI20240628BHEP |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602021030343 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| U01 | Request for unitary effect filed |
Effective date: 20250604 |
|
| U07 | Unitary effect registered |
Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI Effective date: 20250612 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250507 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250808 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250807 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250507 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250507 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250807 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250907 |
|
| U20 | Renewal fee for the european patent with unitary effect paid |
Year of fee payment: 5 Effective date: 20251020 |